News
CELU
3.060
-0.65%
-0.020
Weekly Report: what happened at CELU last week (0429-0503)?
Weekly Report · 1d ago
Weekly Report: what happened at CELU last week (0422-0426)?
Weekly Report · 04/29 09:53
Weekly Report: what happened at CELU last week (0415-0419)?
Weekly Report · 04/22 09:50
Celularity receives Nasdaq notice regarding late Form 10-K filing
Seeking Alpha · 04/19 21:33
Celularity Inc: Statement of changes in beneficial ownership of securities
Press release · 04/17 02:09
Celularity Says That Its Expected Net Sales For Q1 2024 Are Trending Ahead Of The Expectations It Announced In February For Its Advanced Biomaterial Products And Biobanking Businesses; Implements Planned 2024 SG&A Reductions And Manufacturing Ramp For Advanced Biomaterial Products
Expects the First Quarter of 2024 will be the 4th consecutive quarter of both sequential and quarter-on-quarter net sales growth. Celularity's expected net sales for the first quarter of 2024 are trending ahead of the expectations it announced in February. Company developing placental-derived allogeneic cell therapies and advanced biomaterial products. Plan to reduce 2024 selling, general & administrative expenses and executive cash compensation.
Benzinga · 04/15 12:15
Weekly Report: what happened at CELU last week (0408-0412)?
Weekly Report · 04/15 09:47
Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
Celularity Inc. Will present in vitro data from its placenta-derived natural killer cell therapy programs at the American Society of Gene and Cell Therapy Annual Meeting in May 2024. Celularity is a biotechnology company developing cell therapies to address age-related diseases. Senescent cells are key drivers in the process of degenerative diseases and cancer.
Benzinga · 04/08 13:03
Weekly Report: what happened at CELU last week (0401-0405)?
Weekly Report · 04/08 09:48
Weekly Report: what happened at CELU last week (0325-0329)?
Weekly Report · 04/01 09:48
Celularity Receives Healthcare Common Procedure Coding System Q Code Approval From The U.S. Centers For Medicare & Medicaid Services For Biovance 3L
U.S. Centers for Medicare & Medicaid Services has granted a Q code for Biovance® 3L, a tri-layer allograft derived from placental tissue intended for use as a biological membrane covering barrier or wrap. The designated HCPCS Q code is Q4283 and is available starting April 1, 2024. Celularity is a regenerative medicine company developing placental-derived cell therapies.
Benzinga · 03/26 13:02
Weekly Report: what happened at CELU last week (0318-0322)?
Weekly Report · 03/25 09:49
Weekly Report: what happened at CELU last week (0311-0315)?
Weekly Report · 03/18 09:48
Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
Celularity Inc. Will present on the promise of cellular therapy to improve longevity at the ABUNDANCE Summit on March 21, 2024. The company is a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products. Dr. Robert Hariri, M.D., will present at the summit.
Barchart · 03/14 08:15
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NuCana (NASDAQ:NCNA) shares moved upwards by 110.6% to $0.81 during Wednesday's pre-market session. HUTCHMED (China) stock increased by 14.04% in the pre- market session. Kintara Therapeutics (NASdaq:KTRA) and Qilian Intl. Gr (Qilian) were among the losers.
Benzinga · 03/13 13:06
Celularity CEO to Present Keynote Address at 2024 Society for Brain Mapping and Therapeutics Annual World Congress
Dr. Robert Hariri will present the keynote lecture at the Society for Brain Mapping and Therapeutics Annual World Congress on March 16, 2024. Celularity Inc. Is a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products.
Barchart · 03/12 08:20
Weekly Report: what happened at CELU last week (0304-0308)?
Weekly Report · 03/11 09:47
Celularity to Present Data Showing Cancer Tumor Reduction by Off-the-Shelf Cell Therapy Derived from Human Placental Cells
Celularity Inc. Will present in vivo data from its T-cell therapy platform at the AACR Annual Meeting on April 9th, 2024. The data highlight the platform's robust anti-tumor activity against gastric cancer. Celularity is a biotechnology company developing placental-derived allogeneic cell therapies.
Barchart · 03/07 08:35
Weekly Report: what happened at CELU last week (0226-0301)?
Weekly Report · 03/04 09:48
Weekly Report: what happened at CELU last week (0219-0223)?
Weekly Report · 02/26 09:53
More
Webull provides a variety of real-time CELU stock news. You can receive the latest news about Celularity Inc through multiple platforms. This information may help you make smarter investment decisions.
About CELU
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn’s disease.